Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Carcinoma, Renal Cell 5Neoplasms 4Carcinoma, Hepatocellular 4Lung Neoplasms 3Leukemia, Myeloid, Chronic-Phase 3Ovarian Neoplasms 2Neoplasm, Residual 2NSCLC 2Kidney Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms, Second Primary 1Neoplasms by Site 1Lung Diseases 1Liver Neoplasms 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Tyrosine Kinase Inhibitors × Clear all
NCT06632106 2024-10-08

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

First Hospital of China Medical University

Active not recruiting
97 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06232759 2024-06-10

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

Guangxi Medical University

Phase 2 Completed
56 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Bayer

Phase 2 Completed
6 enrolled 11 charts
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT02794337 2022-04-27

TACE-SBRT

Tata Memorial Hospital

Phase 2/3 Unknown
67 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡